Alemtuzumab in the Treatment of Refractory Acute Rejection and Bronchiolitis Obliterans Syndrome After Human Lung Transplantation
Open Access
- 1 December 2007
- journal article
- clinical trial
- Published by Elsevier in American Journal of Transplantation
- Vol. 7 (12) , 2802-2808
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Course of FEV1 after Onset of Bronchiolitis Obliterans Syndrome in Lung Transplant RecipientsAmerican Journal of Respiratory and Critical Care Medicine, 2007
- Acute Cellular Rejection with CD20-Positive Lymphoid Clusters in Kidney Transplant Patients Following Lymphocyte DepletionAmerican Journal of Transplantation, 2007
- Opportunistic Infections in 547 Organ Transplant Recipients Receiving Alemtuzumab, a Humanized Monoclonal CD-52 AntibodyClinical Infectious Diseases, 2007
- Immune Mechanisms of Lung Allograft RejectionSeminars in Respiratory and Critical Care Medicine, 2006
- Registry of the International Society for Heart and Lung Transplantation: Ninth Official Pediatric Lung and Heart–Lung Transplantation Report—2006The Journal of Heart and Lung Transplantation, 2006
- Prope tolerance—the future of organ transplantation from the laboratory to the clinicTransplant Immunology, 2004
- Immunosuppressive therapy after human lung transplantationEuropean Respiratory Journal, 2003
- Is Transplant Operation Important in Determining Posttransplant Risk of Bronchiolitis Obliterans Syndrome in Lung Transplant Recipients?Chest, 2002
- Treatment of refractory acute rejection in a lung transplant recipient with campath 1H.Transplantation, 2002
- Analysis of Risk Factors for the Development of Bronchiolitis Obliterans SyndromeAmerican Journal of Respiratory and Critical Care Medicine, 1999